Thursday, September 14, 2017

4:00 - 6:00 p.m.  Registration

6:00 - 6:10 p.m.  Opening Ceremony and Welcome – Chicago Fairmont Hotel, Imperial Room
F.R. Hirsch, E. Vokes, J. Patel

6:10 - 7:30 p.m.  Keynote Addresses:

6:10 - 6:30 p.m.  Beyond approved PD-1/PD-L1 strategies: Biomarkers besides PD-L1 and IO combinations Likely to change practice in the near term
Hossein Borghaei

6:30 - 6:50 p.m.  On the edge: IO toxicity management and use in patients with underlying autoimmunity
Matthew Hellmann

6:50 - 7:10 p.m.  The interplay of IO and radiation therapy
Roy Decker

7:10 - 7:30 p.m.  Value Frameworks in Cancer Care: A Patient Perspective
Janet Freeman-Daily

7:30 - 9:00 p.m.  Dinner Symposium Sponsored by AstraZeneca
The Role of Immunotherapy for the Management of Patients with Locally Advanced NSCLC
Friday, September 15, 2017

7:00 a.m. - 5:00 p.m.  Registration

8:00 - 9:00 a.m.  Breakfast Symposium Sponsored by AstraZeneca

8:00 - 9:00 a.m.  Breakfast in the registration area

9:00 - 9:05 a.m.  Welcome
Location: Imperial Room

Chairs: Fred Hirsch, Heather Wakelee

9:05 - 9:20 a.m.  Research and Policy Priorities in Tobacco Control  Stephanie Land

9:20 - 9:35 a.m.  Barriers to Widespread Lung Cancer Screening  James Mulshine

9:35 - 9:50 a.m.  Pulmonologists in the Era of Precision Oncology  Colin Gillespie

9:50 - 10:05 a.m.  Optimal tissue utilization in the molecular and IO era  Jeremy Segal

10:05 - 10:20 a.m.  Blood-based Biomarkers in Thoracic Oncology  Max Diehn

10:20 - 10:35 a.m.  Access to care, cost, and health disparities—shifting sands  Robert Winn

10:35 - 11:05 a.m.  Oligometastatic disease and synchronous primaries – optimal approaches  Puneeth Iyengar
Osman Ahmed
Jessica Donington

11:05 - 11:30 a.m.  Break

11:30 a.m. - 1:00 p.m.  Highlighted Oral Session 1
Location: Imperial Room
Session Chairs: Mary Jo Fidler & Jyoti Patel

11:30 - 11:55 a.m.  How BAPI Modulates Gene-Environment Interaction In Carcinogenesis and Renders Tumor Cells Resistant to Chemotherapy  Michele Carbone

11:55 a.m. - 12:03 p.m.  OA01.02
Novel Use of an Electronic Medical Record to Monitor Performance of a Lung Cancer Screening Program  Cherie Erkmen

12:03 - 12:11 p.m.  OA01.03
Attrition Rate in Community-Based Lung Cancer Screening: One and Done  Alexander Carlson
12:11 - 12:19 p.m.  
**OA01.04**  
A Comparability Study Verifying the Analytic Performance of a Blood-based Gene Expression Classifier to Identify Benign Pulmonary Nodules  
Lyssa Friedman

12:19 - 12:26 p.m.  
**Discussant abstracts 67, 85, 132:**  
Joy Feliciano

12:26 - 12:34 p.m.  
**OA01.05**  
Radiation Dose and Fractionation for Limited-Stage Small Cell Lung Cancer: A Survey of US Radiation Oncologists on Practices  
Matthew Farrell

12:34 - 12:50 p.m.  
**Discussant abstract #21:**  
Steven Chmura

1:00 - 2:30 p.m.  
**Lunch Symposia Sponsored by Takeda**

1:00 - 2:30 p.m.  
Lunch in the registration area

2:30 - 3:15 p.m.  
**Education Session 1A & 1B**

2:30 - 3:15 p.m.  
**Breakout Session 1A: Thoracic surgery at the “cutting edge”**  
Location: Imperial Room  
Chair: Malcolm DeCamp

2:30 - 2:40 p.m.  
Multiple lung nodules and GGOs—When to cut?  
Malcolm DeCamp

2:40 - 2:50 p.m.  
Staging updates invasive vs radiographic  
Linda Martin

2:50 - 3:00 p.m.  
Complex resection in pleural diseases (mesothelioma/thymic)  
Linda Martin

3:00 - 3:15 p.m.  
Discussion

2:30 - 3:15 p.m.  
**Breakout Session 1B: Collateral damage in a new era of lung cancer treatment**  
Location: Gold Room  
Chair: Ken Rosenzweig

2:30 - 2:40 p.m.  
Cardio-oncology issues  
Cliff Robinson

2:40 - 2:50 p.m.  
Toxicity concerns with targeted and novel therapies  
Ken Rosenzweig

2:50 - 3:00 p.m.  
Protons for thoracic indications to reduce toxicity  
Jim Urbanic

3:00 - 3:15 p.m.  
Discussion

3:15 - 4:00 p.m.  
**Education Session 2A & 2B**
3:15 - 4:00 p.m. **Breakout Session 2A: Team Based Care in Oncology**  
Location: Imperial Room  
Chair: Kavitha Ramchandran

3:15 - 3:25 p.m. Challenges and Opportunities of Team Based Care  
David Gerber

3:25 - 3:35 p.m. Symptom Management Partnerships  
Kavitha Ramchandran  
Alison Tisch

3:25 - 3:45 p.m. Shared Goal Setting for Elderly Patients with Lung Cancer  
Monica Malec

3:45 - 4:00 p.m. Discussion

3:15 - 4:00 p.m. **Breakout Session 2B: In the Perioperative Setting**  
Location: Gold Room  
Chair: Jamie Chaft

3:15 - 3:25 p.m. Neoadjuvant/Adjuvant Updates  
Jamie Chaft

3:25 - 3:35 p.m. Importance of Lymph node sampling  
Ray Osarogiagbon

3:35 - 3:45 p.m. Surveillance imaging  
Leah Backhus

3:45 - 4:00 p.m. Discussion

4:00 - 4:30 p.m. Break

4:30 - 4:58 p.m. **Education Session 3A & 3B**

4:30 - 4:58 p.m. **Session 3A**  
Location: Imperial Room  
Chair: Larry Feldman

4:30 - 4:38 p.m. **3A.01**  
Efficacy of Programmatic Combined Stereotactic Ablative Radiotherapy and Anti-PD-1 Therapy in Advanced Lung Cancer: A Retrospective Analysis.  
Aparna Hegde

4:38 - 4:46 p.m. **3A.02**  
Major Drivers of Combined Modality Therapy for Limited-Stage Small Cell Lung Cancer in the United States National Cancer  
Stephen Chun

4:46 - 4:58 p.m. Discussant abstract 56 and 112  
Larry Feldman

4:30 - 4:58 p.m. **Session 3B**  
Chair: Tim Kruser  
Location: Gold Room
4:30 - 4:38 p.m.  3B.01  Hematologic Malignancies in Lung Cancer Survivors – the Contribution of Radiation Therapy  
Sarat Appel

4:38 - 4:58 p.m.  Discussant abstract 103  
Tim Kruser

5:05 - 5:45 p.m.  Education Session 4A & 4B

5:05 - 5:45 p.m.  Session 4A  
Location: Imperial Room  
Chair: Fred Hirsch

5:05 - 5:13 p.m.  4A.02  Confirmation of Pathological Diagnosis in Lung Cancer Patients by ctDNA Detection through Ultra-Deep Sequencing  
Geng Tian

5:13 - 5:21 p.m.  4A.03  Predictive Utility of c-reactive Protein (CRP) in Advanced Stage Lung Cancer Treated with Anti-Programmed Cell Death-1 (PD-1)  
Abdul Rafeh Naqash

5:21 - 5:45 p.m.  Discussant abstracts 102, 119  
Fred Hirsch

5:05 - 5:45 p.m.  Session 4B  
Location: Gold Room  
Chair: Ray Osarogiagbon

5:05 - 5:13 p.m.  4B.01  Lung Cancer Patients Migrate to Seek Better Care  
Danh Pham

5:13 - 5:21 p.m.  4B.02  Increasing Survival in Stage IV NSCLC in Academic Versus Community Based Centers in the National Cancer Database  
Sendhilnathan Ramalingam

5:21 - 5:29 p.m.  4B.03  Prospective Evaluation of Multidisciplinary Lung Cancer Care: Timeliness, Thoroughness, and Patient/Caregiver Perspectives  
Matthew Smeltzer

5:29 - 5:45 p.m.  Discussant abstracts 133, 104, 115  
Ray Osarogiagbon

5:50 - 6:35 p.m.  Highlighted Oral Abstract Session 2  
Location: Imperial Room  
Chairs: Nisha Mohindra & Philip Bonomi

5:50 - 5:58 p.m.  OA02.01  Comparison of iRECIST to RECIST1.1 for Following Response to Anti-PD1 Therapy in Patients with Non-Small Cell Lung Cancer  
Sharyn Katz
5:58 - 6:06 p.m.  
**OA02.02**  
Long Term Follow up of Ipilimumab and Targeted Therapy for Metastatic EGFR/ALK Lung Cancer  
Anna Chalmers

6:06 - 6:14 p.m.  
**OA02.03**  
Potential Predictors of Pembrolizumab Associated Pneumonitis: A Retrospective Review of the HCRN LUN 14-179 Trial.  
Shahid Ahmed

6:14 - 6:26 p.m.  
**OA02.04**  
The Cost and the Benefit: Front-Line Immunotherapy For Non-Small Cell Lung Cancer  
Christine Bestvina

6:26 - 6:35 p.m.  
**Discussant abstracts 138, 79, 106 and 80:**  
Hossein Borghaei

6:35 - 7:30 p.m.  
**Poster Viewing and Reception**

7:30 - 9:30 p.m.  
**Dinner Symposium Sponsored by Bristol-Meyers Squibb, Genentech, Inc. and Merck & Co., Inc.**  
Location: Gold Room

7:30 - 9:30 p.m.  
**Dinner Symposium Sponsored by AstraZeneca**  
Location: Imperial Room
Saturday, September 16, 2017

7:00 a.m. - 1:00 p.m.  Registration

6:30 - 8:00 a.m.  Breakfast Symposium Sponsored by AstraZeneca – New Options and Evolving Strategies for Hitting the Target in EGFR-Mutant NSCLC

7:00 - 8:00 a.m.  Breakfast in the registration area

8:00 - 8:45 a.m.  Tumor Board  Moderated by Tim Murgu

Faculty:  Jeff Mueller, Jessica Donington, Tim Kruser, Doug Arenberg, Tom Hensing, Heather Wakelee

8:45 - 10:15 a.m.  Highlighted Oral Session 3
Imperial Room
Chairs: Tom Hensing & Matt Steliga

8:45 - 8:53 a.m.  OA03.01  Andrew Nagy
Outcomes of Integrating Smoking Cessation Counseling in a Lung Cancer Screening Program

8:53 - 9:01 a.m.  OA03.02  Paul Walker
An Intervention Study to Reduce Black-White Treatment Disparities in Early Stage Non-Small Cell Lung Cancer

9:01 - 9:09 a.m.  OA03.03  Bretta McCall
Community Network Lung Cancer Screening Experience Underrepresents Medically Underserved and Geographically Remote Individuals

9:09 - 9:21 a.m.  Discussant abstracts 41, 49, 87 by:  Matthew Steliga

9:21 - 9:29 a.m.  OA03.04  Christopher Strouse
Radiation Therapy Before Anti-PD1 Therapy Not Associated with Survival Difference; Single Institution Retrospective Review

9:29 - 9:37 a.m.  OA03.05  Aparna Hegde
Tocilizumab for the Management of Immune Mediated Adverse Events Secondary to PD-1 Blockade: Overall Survival Analysis

9:37 - 9:49 a.m.  Discussant abstracts 136, 60 by:  Heather Wakelee
9:49 - 10:01 a.m. OA03.06 Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma

10:01 - 10:09 a.m. OA03.07 Dabrafenib and Trametinib Combination Therapy versus Docetaxel in Previously Treated Metastatic NSCLC: An Adjusted Indirect Comparison

10:09 - 10:17 a.m. OA03.08 Activity of Ensartinib after Second Generation Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKI)

10:17 - 10:30 a.m. Discussant abstracts 42, 23, 147 by: Tom Stinchcombe

10:30 - 10:45 a.m. Break

10:45 - 12:00 p.m. Year in Review Session chair: Everett Vokes

10:45 - 11:00 a.m. Beyond EGFR and ALK

11:00 - 11:15 a.m. Staging Updates – AJCC updates

11:15 - 11:30 a.m. Debate: Patients with EGFR mutation NSCLC should postpone brain radiation for brain metastasis

11:15 - 11:22 a.m. Pro: Lecia Sequist
11:22 - 11:29 a.m. Con: Laurie Gaspar

11:30 - 11:45 a.m. Debate: All patients with NSCLC Should Receive Immunotherapy 1st Line

11:30 - 11:37 a.m. Pro: Jyoti Patel
11:37 - 11:44 a.m. Con: John Heymach

11:45 a.m. - noon Stage III NSCLC-current status, next steps